Home > Insider Trading > Filing (0001689813-19-000096)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1689813	Biohaven Pharmaceutical Holding Co Ltd.	BHVN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1704186	Kimberly Gentile	C/O Biohaven Pharmaceuticals, Inc., 215 Church Street New Haven CT 06510	Svp, Clinical Operations	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares	Acquisiton	2019-11-20	3,935	$0.61	3,935	No	4	M	Direct
Common Shares	Disposition	2019-11-20	3,935	$53.03	0	No	4	S	Direct
Common Shares	Acquisiton	2019-11-21	21,065	$0.61	21,065	No	4	M	Direct
Common Shares	Disposition	2019-11-21	21,065	$53.04	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Employee Stock Option (Right to Buy)	Disposition	2019-11-20	3,935	$0.00	3,935	$0.61
Common Shares	Employee Stock Option (Right to Buy)	Disposition	2019-11-21	21,065	$0.00	21,065	$0.61

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
21,065		2024-11-25	No	4	M	Direct
0		2024-11-25	No	4	M	Direct

Footnotes

These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 - $53.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 - $53.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The option, representing a right to purchase a total of 62,500 shares, was granted on November 26, 2014, and vested in four equal installments on November 26, 2014, 2015, 2016 and 2017. The optionholder previously exercised the option with respect to an aggregate of 37,500 shares during 2017 and 2018.